Clinical trials: Gemcitabine
Carcinoma, Pancreatic Ductal, Pancreatic Cancer
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A study to evaluate AGS-1C4D4 administered in combination with Gemcitabine chemotherapy in subjects with Metastatic Pancreatic Cancer.
- Conditions
- Carcinoma, Pancreatic Ductal, Pancreatic Cancer, Pancreatic Disease
- Trial name
- NCT00902291
- Testing
- AGS-1C4D4, Gemcitabine
- Where
- 36 sites in United States, Canada and 3 more
- Volunteers
- 205 people
- Sponsor
- Astellas Pharma Inc
Metastatic Pancreatic Cancer
Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients
This randomized, Phase 2, open label study aims to assess the efficacy and safety of gemcitabine + nab paclitaxel with or without dociparstat (ODSH) as first line treatment of metastatic pancreatic cancer.
- Trial name
- PGPC1 (NCT01461915)
- Testing
- Nab paclitaxel, Gemcitabine, Dociparstat
- Where
- 16 sites in United States
- Volunteers
- 60 people
- Sponsor
- Jazz Pharmaceuticals
Advanced Solid Tumor
Safety and Pharmacokinetic Profiles of Two Formulations of CO-1.01 in Patients With Advanced Solid Tumors
The purpose of this study is to compare the pharmacokinetic and safety profiles of two formulations of CO-1.01 in patients with Advanced Solid Tumors.
- Trial name
- NCT01392976
- Testing
- CO-1.01 Formulation A (Aqueous suspension containing 15 mg/mL of drug solubilized in purified phospholipids), CO-1.01 Formulation B (Aqueous suspension containing 30 mg/mL of drug solubilized in purified phospholipids)
- Where
- 3 sites in Netherlands
- Volunteers
- 17 people
- Sponsor
- Clovis Oncology, Inc.
Advanced Cancer, Metastatic Cervical Cancer
Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)
This Phase 3 trial is an open-label, randomized study with single-agent Balstilimab (BAL) or Investigator Choice (IC) chemotherapy (single-agent gemcitabine, irinotecan, pemetrexed, vinorelbine, or topotecan) in patients with…
- Trial name
- NCT04943627
- Testing
- Balstilimab (BAL), Topotecan, Vinorelbine
- Where
- 3 sites in United States, Armenia
- Sponsor
- Agenus Inc.
Gastric Cancer, Gastroesophageal Junction Cancer
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with locally advanced…
- Conditions
- Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06219941
- Testing
- AZD0901, 5-Fluorouracil, Leucovorin
- Where
- 52 sites in United States, Australia and 12 more
- Volunteers
- 226 people
- Sponsor
- AstraZeneca
Non-Small-Cell Lung Cancer
Pemetrexed and Gemcitabine Every 14 Days Versus Every 21 Days in Advanced Non Small Cell Lung Cancer
This study is designed to evaluate Pemetrexed and Gemcitabine Day 1 followed by Gemcitabine Day 8 every 21 days (Arm A) and Pemetrexed and Gemcitabine Day 1 every 14 days (Arm B) in patients with NSCLC.
- Trial name
- NCT00383331
- Testing
- Pemetrexed, Gemcitabine
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab.
- Trial name
- NCT06623422
- Testing
- Pembrolizumab, Cisplatin, Carboplatin
- Where
- 245 sites in United States, Argentina and 29 more
- Volunteers
- 680 people
- Sponsor
- Merck Sharp & Dohme LLC
Urinary Bladder Neoplasms
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
The purpose of this study is to evaluate the overall complete response (CR) rate in participants treated with TAR-200 in combination with cetrelimab (Cohort 1), or TAR-200 alone (Cohort 2), or cetrelimab alone (Cohort 3) with…
- Trial name
- SunRISe-1 (NCT04640623)
- Testing
- TAR-200, Cetrelimab
- Where
- 144 sites in United States, Australia and 14 more
- Volunteers
- 220 people
- Sponsor
- Janssen Research & Development, LLC
Diffuse Large B-cell Lymphoma
A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma
This is a multicenter, randomized, open-label, phase 3 clinical study to evaluate the efficacy of SHR-A1912 combined with R-GemOx in relapsed refractory diffuse large B-cell lymphoma.
- Trial name
- NCT06929624
- Testing
- SHR-A1912 Injection, Rituximab Injection, Gemcitabine Hydrochloride for Injection
- Where
- 2 sites in China
- Volunteers
- 282 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Metastatic Pancreatic Adenocarcinoma
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer
This is an open label, multi-center, multi-arm, dose-escalation study of BBI608 administered in combination with Gemcitabine and nab-Paclitaxel, mFOLFIRINOX, FOLFIRI, or MM-398 with 5-FU and leucovorin.
- Trial name
- NCT02231723
- Testing
- BBI608, Nab-paclitaxel, Gemcitabine
- Where
- 12 sites in United States
- Volunteers
- 139 people
- Sponsor
- Sumitomo Pharma America, Inc.
Advanced Pancreatic Cancer
A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer
The purpose of this study is to determine whether an investigational immuno-therapy, cabiralizumab in combination with nivolumab, with or without chemotherapy, is effective for the treatment of advanced pancreatic cancer.
- Trial name
- NCT03336216
- Testing
- Cabiralizumab, Nab-paclitaxel, Onivyde
- Where
- 41 sites in United States, Canada and 9 more
- Volunteers
- 205 people
- Sponsor
- Bristol-Myers Squibb
Solid Tumors
A Study of LY2603618 in Combination With Gemcitabine in Participants With Solid Tumors
The primary objective of this study is to evaluate the safety and tolerability of LY2603618 in combination with the standard dose of gemcitabine up to the global recommended dose of LY2603618 in Japanese participants with solid…
- Trial name
- NCT01341457
- Testing
- LY2603618, Gemcitabine
- Where
- Japan
- Volunteers
- 17 people
- Sponsor
- Eli Lilly and Company
Biliary Tract Cancers (BTC)
A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract Cancers
Unresectable BTC represents an area of unmet medical need due to its very aggressive nature, limited treatment options, and poor prognosis.
- Trial name
- NCT06611345
- Testing
- Tumor Treating Fields, Durvalumab, Gemcitabine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
Carcinoma, Non-Small-Cell Lung
Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to compare combination treatment of gemcitabine + oxaliplatin (GEMOX) with carboplatin + paclitaxel (CP) to determine if there is a difference in response and safety between the two drug combinations…
- Trial name
- NCT00087802
- Testing
- gemcitabine/Eloxatin (GEMOX), carboplatin/paclitaxel (CP)
- Where
- 70 sites in United States
- Volunteers
- 383 people
- Sponsor
- Sanofi
Advanced Solid Tumours
AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer
This is a phase Ib/II, open-label multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of AZD9150 plus durvalumab alone or in combination with chemotherapy in patients with…
- Trial name
- NCT03421353
- Testing
- AZD9150, Durvalumab, Cisplatin
- Where
- 6 sites in United States
- Volunteers
- 76 people
- Sponsor
- AstraZeneca
Solid Tumors or Mantle Cell Lymphoma
Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma
The primary objective of the study is to determine the maximum tolerated dose (MTD) of CEP-9722 in combination with gemcitabine and cisplatin in patients with advanced solid tumors or mantle cell lymphoma.
- Trial name
- NCT01345357
- Testing
- CEP-9722, Gemcitabine, Cisplatin
- Where
- 3 sites in Belgium, France
- Volunteers
- 24 people
- Sponsor
- Cephalon
Pancreatic Adenocarcinoma
Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma
This is a Phase 1b/2 study of batiraxcept (AVB-S6-500) designed to evaluate the safety and efficacy of batiraxcept in combination with nab-paclitaxel and gemcitabine in subjects with locally advanced, recurrent, or metastatic…
- Trial name
- NCT04983407
- Testing
- batiraxcept, Nab paclitaxel, Gemcitabine
- Where
- 17 sites in United States
- Volunteers
- 34 people
- Sponsor
- Aravive, Inc.
Carcinoma, Non-Small-Cell Lung
A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC)
Evaluation of gemcitabine and cisplatin in combination with either sorafenib or placebo for the treatment of patients with advanced Non-Small Cell Lung Cancer (NSCLC)
- Trial name
- NEXUS (NCT00449033)
- Testing
- Sorafenib (Nexavar, BAY43-9006), Gemcitabine, Cisplatin
- Where
- 122 sites in Austria, Belgium and 16 more
- Volunteers
- 904 people
- Sponsor
- Bayer
Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
The purpose of this study is to evaluate the efficacy of loncastuximab tesirine (ADCT-402) combined with rituximab compared to standard immunochemotherapy.
- Trial name
- LOTIS 5 (NCT04384484)
- Testing
- Loncastuximab Tesirine, Rituximab, Gemcitabine
- Where
- 144 sites in United States, Argentina and 19 more
- Volunteers
- 440 people
- Sponsor
- ADC Therapeutics S.A.
Pancreatic Cancer
A Study of Capecitabine (Xeloda) in Participants With Locally Advanced or Metastatic Pancreatic Cancer
This study will evaluate the efficacy and safety of oral capecitabine plus intravenous (IV) gemcitabine in participants with locally advanced or metastatic pancreatic cancer.
- Trial name
- NCT02565641
- Testing
- Capecitabine, Gemcitabine
- Where
- 7 sites in South Korea
- Volunteers
- 63 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.